Drug Pricing: Page 3
-
Courtesy of Eisai
New Alzheimer's drugsEisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.
By Ned Pagliarulo • Jan. 6, 2023 -
Pharma companies boost drug prices to start year, but hikes lag inflation
Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.
By Jonathan Gardner • Jan. 3, 2023 -
Explore the Trendline➔
Roche
TrendlineBiosimilars
The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars.
By BioPharma Dive staff -
Permission granted by Bluebird bio
Gene therapy approval won, Bluebird takes on next challenge: selling it
The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.
By Ned Pagliarulo • Dec. 12, 2022 -
Hinterhaus Productions via Getty Images
Sponsored by First Republic BankLife science investment outlook: thinking beyond the pandemic
Learn about the investment landscape for life science companies, heading into 2023.
Dec. 12, 2022 -
Anna Moneymaker/Getty Images via Getty Images
Sanders poised to lead Senate health committee
The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.
By Susan Kelly • Nov. 28, 2022 -
FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar
Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.
By Christopher Newman • Nov. 18, 2022 -
Rebecca Pifer/BioPharma Dive
Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says
The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.
By Rebecca Pifer • Nov. 16, 2022 -
Courtesy of EQRx
EQRx redraws ‘radical’ drug pricing plans for first two drugs
The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.
By Jonathan Gardner • Nov. 10, 2022 -
zorazhuang via Getty Images
Pharma earnings outline drug law’s looming impact on sales, development
While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.
By Christopher Newman • Nov. 9, 2022 -
Khanchit+khirisutchaluai/Shutterstock.com
Sponsored by GoodRxInflation Reduction Act: What are the healthcare implications?
The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.
Oct. 31, 2022 -
Sponsored by GoodRx
Worried about provider consolidation? Learn about GoodRx engagement solutions
GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.
Oct. 10, 2022 -
Permission granted by Amylyx Pharmaceuticals
ALS drug developmentAmylyx sets ALS drug price at $158,000 per year, opening new debate on cost
The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.
By Jacob Bell • Sept. 30, 2022 -
Novartis
Novartis warns of sales hit after federal court turns back patent appeal
The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.
By Kristin Jensen • Sept. 21, 2022 -
Jeff J Mitchell via Getty Images
Deep DiveCan biosimilars, after years of limited impact, finally make a mark in the US?
Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.
By Jonathan Gardner • Sept. 7, 2022 -
Permission granted by Akili Inc.
Q&AAkili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment
With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.
By Elise Reuter • Aug. 29, 2022 -
Courtesy of BioMarin Pharmaceutical
With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.
By Jacob Bell • Aug. 25, 2022 -
Permission granted by Bluebird bio
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.
By Ned Pagliarulo • Aug. 18, 2022 -
Drew Angerer/Getty Images via Getty Images
Pharma industry braces as drug pricing bill passes Congress
The Inflation Reduction Act, signed into law by President Biden in August, was one of the most significant political defeats for the industry in years, and will reshape companies’ business plans moving forward.
By Christopher Newman • Aug. 15, 2022 -
Drew Angerer/Getty Images via Getty Images
Senate passage of drug pricing bill brings major defeat closer for pharma industry
The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.
By Christopher Newman • Aug. 8, 2022 -
iStock via Getty Images
Pharma CEOs press case against drug price negotiation as bill gains support
On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.
By Christopher Newman • Aug. 4, 2022 -
DKosig via Getty Images
Roche digs deeper into gene therapy for the eye
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
By Jonathan Gardner • July 20, 2022 -
UnitedHealth Group
UnitedHealth to offer some drugs, including insulin, at no cost share in 2023
The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.
By Rebecca Pifer • July 15, 2022 -
Justin Sullivan via Getty Images
California to manufacture its own insulin, governor says
Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”
By Susan Kelly • July 11, 2022 -
Elizabeth Regan / Industry Dive
Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost
ICER, an influential nonprofit, suggested in a draft report that Amylyx’s closely watched ALS treatment would not be cost effective if priced on par with a currently available treatment.
By Ned Pagliarulo • Updated June 14, 2022 -
Roche
Roche SMA drug approved in youngest infants, challenging Novartis and Biogen
Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.
By Jonathan Gardner • May 31, 2022
Previous
